

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

January 28, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. Script Code: WANBURY
---	--

Dear Sir/Madam,

Sub: Press Release

Please find attached a Press Release with titled “Wanbury launches commercial production of key anaesthetic API at Tanuku Facility. The Company targets incremental Rs.100 Crore + revenue from new products in FY 2026-27”

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra J. Gandhi
Company Secretary





Wanbury Launches Commercial production of key anaesthetic API at Tanuku Facility. The Company targets incremental Rs.100 Crore + revenue from new products in FY 2026-27.

27th January 2026, MUMBAI: Wanbury Limited, a leading pharmaceutical company with a good legacy in domestic and global API markets and branded formulations today announced the commencement of commercial production for a high-potent anaesthetic API at its state-of-the-art facility in Tanuku, Andhra Pradesh. This milestone positions the company to capture robust revenue growth for Q4FY26 and FY27. The new API is expected to generate incremental revenues of approximately Rs. 18 crore in Q4 FY 2025-26.

Complementing this achievement, Wanbury's upcoming multi-purpose intermediate production block at Tanuku is on track for commercial readiness by the end of March 2026. This versatile facility will enable the production of four additional high-value APIs: Antidiabetic, Anticoagulant (Blood thinner), Cough suppressant (Anti Tussive), Antidepressant. Together, these four molecules are projected to deliver over Rs. 100 crore in revenues for Wanbury in FY 2026-27, fuelled by strong global demand. The worldwide market for these new APIs is currently valued at over Rs. 5,000 crore, presenting substantial growth opportunities.

Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said:

“We are excited about this strategic expansion, which strengthens our API portfolio and underscores our commitment to meeting global healthcare needs with reliable, high-quality supply of API”.



About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, Ketamine Hydrochloride and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact

Jitendra J. Gandhi

Company Secretary,

Wanbury Limited

BSEL Techpark, B-Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703,
Maharashtra, India.

Tel: +91-22-6794 2222

Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal

Adfactors PR

Oasis Complex, Kamala Mills Compound,
City Hall, Pandurang Budhkar Marg, Lower
Parel West, Mumbai - 400 021.
Maharashtra, India.

Tel: +91 9619059339 / +91 7021852071

Email: hanishi.shah@adfactorspr.com

anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.
